Valuation: Rezolute, Inc.

Market Cap 443M 397M 367M 333M 621M 42.16B 629M 4.39B 1.75B 22.06B 1.66B 1.63B 70.04B P/E 2027 *
-5.97x
P/E 2028 * -8.16x
Enterprise Value 443M 397M 367M 333M 621M 42.16B 629M 4.39B 1.75B 22.06B 1.66B 1.63B 70.04B EV / Sales 2027 *
211x
EV / Sales 2028 * 8.18x
Free-Float
89.96%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Rezolute, Inc.

1 day+2.68%
1 week+14.05%
Current month+1.93%
1 month+0.96%
3 months-14.23%
6 months+37.46%
Current year+78.81%
1 week 3.7
Extreme 3.7
4.24
1 month 3.37
Extreme 3.37
4.91
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
70
Manager TitleAgeSince
Chief Executive Officer 59 30/01/2013
Director of Finance/CFO 53 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 59 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Tax

Executive/Senior Manager

-2,267 0.0024%
7/2/26 A Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Financial Officer

-3,062 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
+2.68%+14.05%-55.53%+328.43% 431M
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-2.59%-0.31%+23.35%-10.65% 23.36B
Average +3.74%+1.45%+41.55%+178.62% 38.09B
Weighted average by Cap. +2.85%+0.21%+47.90%+161.19%

Financials

2027 *2028 *
Net sales 2.09M 1.88M 1.74M 1.57M 2.94M 199M 2.98M 20.77M 8.27M 104M 7.86M 7.69M 331M 54.09M 48.53M 44.87M 40.63M 75.92M 5.15B 76.83M 536M 214M 2.7B 203M 199M 8.56B
Net income -79.49M -71.31M -65.93M -59.71M -112M -7.57B -113M -788M -314M -3.96B -298M -292M -12.58B -59.93M -53.77M -49.71M -45.02M -84.12M -5.71B -85.13M -594M -237M -2.99B -225M -220M -9.48B
Net Debt - -
Projected Income Statement - Annual - Rezolute, Inc.
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
58
Date Price Change Volume
28/10/26 $4.220 +2.68% 1,414,519
27/10/26 $4.110 +7.59% 1,400,114
26/10/26 $3.820 -0.91% 1,543,500
23/10/26 $3.855 -0.13% 1,198,115
22/10/26 $3.860 +4.32% 1,355,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rezolute, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.220USD
Average target price
9.800USD
Spread / Average Target
+132.23%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rezolute, Inc.
  1. Stock Market
  2. Stocks
  3. RZLT Stock